

*Do NOT Enter
Dk III 105 UW*

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for diagnosing prostate cancer, the method comprising the step of detecting ~~the presence or absence of an increased levels expression product of a human endogenous MMTV-like subgroup 2 (HML-2) retrovirus encoded expression product in a patient prostate or blood sample relative to a negative control sample.~~
2. (Previously Presented) The method of claim 1 wherein the expression product is an RNA or a polypeptide.
3. (Currently Amended) The method of claim 1 wherein the patient sample is a prostate sample ~~or a blood sample.~~
4. (Previously Presented) The method of claim 1 wherein the expression product is an RNA comprising SEQ ID NO:155.
5. (Previously Presented) The method of claim 4 wherein the expression product is an RNA comprising SEQ ID NO:5.
6. (Previously Presented) The method of claim 4 wherein SEQ ID NO:155 is at the 5' end of the RNA.
7. (Currently Amended) The method of claim 1 or 2 wherein the RNA comprises SEQ ID NO:155 and SEQ ID NO:5.
8. (Canceled)
9. (Previously Presented) The method of claim 2 wherein the expression product is a polypeptide and wherein the polypeptide is selected from the group consisting of gag, prt, pol, env, cORF, and tat.